Citations

1. Jonsson R, et al. (2005). Sjögren's syndrome. In WJ Koopman, LW Moreland, eds., Arthritis and Allied Conditions: A Textbook of Rheumatology, 15th ed., vol. 2, pp. 1681–1705. Philadelphia: Lippincott Williams and Wilkins.

2. Fox RI (2000). Sjögren's syndrome: Current therapies remain inadequate for a common disease. Expert Opinion on Investigational Drugs, 9(9): 2007–2016.

3. Fox RI, et al. (2000). Update in Sjögren syndrome. Current Opinion in Rheumatology, 12(5): 391–398.

4. Petrone D, et al. (2002). A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis and Rheumatism, 46(3): 748–754.

5. Fife RS, et al. (2002). Cevimeline for the treatment of xerostomia in patients with Sjögren's syndrome. Archives of Internal Medicine, 162: 1293–1300.

6. Carsons S (2005). Sjögren's syndrome. In ED Harris Jr et al., eds., Kelley's Textbook of Rheumatology, 7th ed., vol. 2, chap. 69, pp. 1105–1124. Philadelphia: Elsevier Saunders.

7. Ophthalmic cyclosporine (Restatis) for dry eye disease (2003). Medical Letter on Drugs and Therapeutics, 45(W1157B): 42–43.

8. Steinfeld SD, et al. (2002). Infliximab in primary Sjögren's syndrome. Arthritis and Rheumatism, 46(12): 3301–3303.